WANBURY
Back to Balance Sheet
|
WANBURY Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹173 Cr | ₹99 Cr | ₹11 Cr | ₹11 Cr | ₹84 Cr |
What is the latest Total Non-Current Liabilities ratio of WANBURY ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹173 Cr |
| Mar2024 | ₹99 Cr |
| Mar2023 | ₹11 Cr |
| Mar2022 | ₹11 Cr |
| Mar2021 | ₹84 Cr |
How is Total Non-Current Liabilities of WANBURY Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹173 Cr | 74.78 | |
| Mar2024 | ₹99 Cr | 815.56 | |
| Mar2023 | ₹11 Cr | 2.34 | |
| Mar2022 | ₹11 Cr | -87.49 | |
| Mar2021 | ₹84 Cr | - | |
Compare Total Non-Current Liabilities of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹958.0 Cr | -2.3% | 2.3% | -11.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹433,620.0 Cr | 0.6% | -2.8% | 6.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹176,087.0 Cr | 0.4% | 0.1% | 0.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹154,837.0 Cr | 3.4% | 4.3% | 42% | Stock Analytics | |
| CIPLA | ₹112,194.0 Cr | -1.3% | 7% | -7.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,328.0 Cr | -0.2% | 0.4% | -1.4% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | -2.3% |
2.3% |
-11.6% |
| SENSEX | 1.7% |
1.3% |
-7.3% |
You may also like the below Video Courses